SPAST

Across TCGA pan-cancer cohorts, SPAST mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPAST data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPAST mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPAST expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where SPAST mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	1.000	0.837	.005	8	view →
CCRCC	DFS	Median	All	0.709	1.000	.010	2	view →
PDAC	DFS	Tertile	III,IV	0.560	0.901	.033	2	view →
HNSC	DFS	Median	IV	0.606	0.762	.046	1	view →
GBM	OS	Median	All	0.657	0.859	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPAST–LSCC (DFS)

Open the LSCC breakdown →